drugset / Trial / NCT02093169

D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound

NCT02093169

Phase 1 Completed 12 enrolled H. Lundbeck A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To investigate the relationship between the combined Lu AF35700 and Lu AF36152 plasma concentration and D2 dopamine receptor occupancy up to 172 hours after oral dosing of Lu AF35700

Timeline

Start
2014-02
Primary completion
2014-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AF35700 Unknown 30 mg Oral
Subject Lu AF35700 Unknown 45 mg Oral

Indications

No indication recorded.